May 2006
Volume 47, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2006
Scleral Drug Delivery Using Microneedles
Author Affiliations & Notes
  • N. Jiang
    Chemical and Biomolecular Engineering, Georgia Institute of Technology, Atlanta, GA
  • D. Ghate
    Ophthalmology, Emory University, Atlanta, GA
  • B.E. McCarey
    Ophthalmology, Emory University, Atlanta, GA
  • D.H. Geroski
    Ophthalmology, Emory University, Atlanta, GA
  • M.R. Prausnitz
    Chemical and Biomolecular Engineering, Georgia Institute of Technology, Atlanta, GA
  • H.F. Edelhauser
    Ophthalmology, Emory University, Atlanta, GA
  • Footnotes
    Commercial Relationships  N. Jiang, None; D. Ghate, None; B.E. McCarey, None; D.H. Geroski, None; M.R. Prausnitz, None; H.F. Edelhauser, None.
  • Footnotes
    Support  NEI T32–EY07092
Investigative Ophthalmology & Visual Science May 2006, Vol.47, 3881. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      N. Jiang, D. Ghate, B.E. McCarey, D.H. Geroski, M.R. Prausnitz, H.F. Edelhauser; Scleral Drug Delivery Using Microneedles . Invest. Ophthalmol. Vis. Sci. 2006;47(13):3881.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To treat inflammatory and proliferative diseases in the posterior segment, it is difficult to deliver effective drug doses to the back of the eye using conventional delivery methods such as topical application and systemic administration. In this study, we adapted microfabrication technology to develop microscopic needles that penetrate just hundreds of microns into the sclera to deliver drugs to the back of the eye in a minimally invasive manner. We assessed whether (1) hollow microneedles could be used to microinject drug solution into the sclera and (2) solid microneedles coated with drug formulations could rapidly release their drug coatings by dissolution within ocular tissue.

Methods: : To assess hollow microneedles for intrascleral microinjection, a hollow glass microneedle was inserted into human cadaver sclera for infusion of sulforhodamine solution at 5 – 20 psi. To assess solid microneedles for intraocular delivery, solid metal microneedles coated with sodium fluorescein were inserted into rabbit cornea in vivo. After needle removal, fluorescein concentration in the anterior segment was measured for ≤ 24 h.

Results: : Hollow microneedles were shown to insert into, but not across, human cadaver sclera and inject model drug solutions into the sclera. Microinjection volume increased with increasing pressure; up to 100 µl was injected within 5 mins at 20 psi. Solid metal microneedles were shown to insert into rabbit sclera in vivo. Sodium fluorescein completely dissolved off the needles within 3 min, which resulting in fluorescein concentrations in the anterior chamber 100 times greater that those achieved by topical delivery of fluorescein in the absence of microneedles. No inflammatory response or other adverse effects were observed when using microneedles.

Conclusions: : For the first time, microneedles were shown to penetrate into sclera in vitro and cornea in vivo and to deliver useful quantities of model drugs into the ocular tissues. Microneedles may provide a minimally invasive method to deliver drugs into the sclera to treat diseases in the posterior segment that avoids the complications associated with intraocular injection and systemic administration.

Keywords: sclera • anterior segment 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×